

Abstract

The invention relates to a method of preventing or treating proliferative diseases such as cancer in a mammal, particularly a human, with a combination of pharmaceutical agents which comprises: (a) an HDAI; and (b) a death receptor ligand. The invention further relates to pharmaceutical compositions comprising: (a) an HDAI; (b) death receptor ligand; and (c) a pharmaceutically acceptable carrier. The present invention further relates to a commercial package or product comprising: (a) a pharmaceutical formulation of an HDAI; and (b) a pharmaceutical formulation of death receptor ligand for simultaneous, concurrent, separate or sequential use.